CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner

Abstract

Chemoresistance is the main cause of treatment failure and high mortality in advanced lung cancer. Cisplatin, an important chemotherapeutic agent for lung cancer, has been observed to show enormously reduced chemotherapeutic efficacy owing to the development of chemoresistance. CXCR4, a stromal-derived-factor-1 specific chemokine receptor, is highly expressed in non-small cell lung cancer (NSCLC) tissues and participates in cancer progression by regulating cell growth, apoptosis or invasion. In this study, we therefore investigated whether CXCR4 plays a role in the cisplatin associated resistance in NSCLC. We detected the expression of CXCR4 in tissue specimens from 64 NSCLC patients by immunohistochemistry. Cisplatin-resistant NSCLC cells A549/DDP and its parental A549 cells were employed in this study. RNA interference was performed to silence the CXCR4. The influence of CXCR4 on tumor cell chemoresistance, apoptosis and growth, as well as the relationship between CXCR4 and the expression of cytochrome p450 associated molecule CYP1B1 in NSCLC were evaluated. Finally, we found CXCR4 was significantly highly expressed in cisplatin-resistant NSCLC patients and the A549/DDP cell line. CXCR4 inhibition by siRNA reversed chemoresistance and decreased tumor cell proliferation. Bioinformatics analysis showed that the expression of CYP1B1 had a positive correlation with CXCR4, the CYP1B1 silencing significantly decreased CXCR4 expression levels and cisplatin resistance. Immunohistochemistry also verified that CYP1B1 was upregulated in NSCLC tissues of cisplatin-resistant patients. In conclusion, our results indicate that overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. Thus, it can be used as a potential therapeutic target in NSCLC chemoresistance patients and be used as a clinical predictor of cisplatin response.

Placenta‑derived mesenchymal stem cells ameliorate lipopolysaccharide‑induced inflammation in RAW264.7 cells and acute lung injury in rats

“…pMSC downregulates CXCL12 in LPS-induced ALI. in our previous studies it was demonstrated that the activation of the cXcl12/cXcr4 axis played an important role in the metastasis and drug resistance in lung cancer (26)(27)(28). Moreover, cXcl12 could serve as pro-inflammatory chemokines as was reported in some previous studies (17,18).…”

High co-expression of the SDF1/CXCR4 axis in hepatocarcinoma cells is regulated by AnnexinA7 in vitro and in vivo

“…It has been shown that CXCR4 is increased by 2–15 times in ovarian cancer cells compared to normal ovarian cells at the mRNA level [ 15 , 16 ]. Some studies have found that SDF1 and CXCR4 are highly expressed in cholangiocarcinoma [ 17 ], breast cancer [ 18 ], non-small cell lung cancer [ 19 , 20 ], cervical cancer [ 21 , 22 ], liver cancer Huh7 cells [ 23 ] and melanoma cells [ 24 ]. Hypoxia also induces the expression of SDF1/CXCR4 in tumor cells [ 25 , 26 ].…”

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cellsin vitro

“…In platinum-resistant cells, several molecular mechanisms, such as increased DNA-repair capacity or the alteration of DNA-damage associated pathways, result in apoptosis inhibition and cell survival, following cisplatin treatment [ 17 ]. In platinum-resistant A2780cis cells, we observed a 5-FdU-ECyd mediated activation of cytochrome p450 drug metabolization pathways, which are known to confer chemo-resistance [ 35 ]. Interestingly, although these pathways were activated, the antitumor effect of 5-FdU-ECyd was not impaired at all in these cells.…”